New Risk • 11h
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 274% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr23m free cash flow). Share price has been highly volatile over the past 3 months (24% average weekly change). Earnings have declined by 10% per year over the past 5 years. Shareholders have been substantially diluted in the past year (274% increase in shares outstanding). Market cap is less than US$10m (kr57.0m market cap, or US$6.09m). Reported Earnings • May 05
First quarter 2026 earnings released First quarter 2026 results: Revenue: kr15.1m (up 2.0% from 1Q 2025). Net loss: kr6.67m (loss narrowed 27% from 1Q 2025). Aankondiging • Apr 27
LifeClean International AB (publ), Annual General Meeting, May 27, 2026 LifeClean International AB (publ), Annual General Meeting, May 27, 2026, at 13:00 W. Europe Standard Time. Location: at born laws premises, strandvagen 7a, stockholm Sweden Reported Earnings • Feb 09
Full year 2025 earnings released: kr0.13 loss per share (vs kr0.97 loss in FY 2024) Full year 2025 results: kr0.13 loss per share (improved from kr0.97 loss in FY 2024). Revenue: kr55.4m (down 9.4% from FY 2024). Net loss: kr35.7m (loss narrowed 34% from FY 2024). Board Change • Feb 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. Independent Director Karin Fischer was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 24
Third quarter 2025 earnings released Third quarter 2025 results: Revenue: kr9.49m (down 32% from 3Q 2024). Net loss: kr10.2m (loss narrowed 23% from 3Q 2024). New Risk • Aug 14
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 36% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr35m free cash flow). Share price has been highly volatile over the past 3 months (36% average weekly change). Earnings have declined by 30% per year over the past 5 years. Shareholders have been substantially diluted in the past year (393% increase in shares outstanding). Market cap is less than US$10m (kr71.3m market cap, or US$7.44m). Reported Earnings • Jul 16
Second quarter 2025 earnings released Second quarter 2025 results: Revenue: kr20.5m (down 2.3% from 2Q 2024). Net loss: kr7.18m (loss narrowed 44% from 2Q 2024). Aankondiging • May 28
LifeClean International AB (publ), Annual General Meeting, Jun 30, 2025 LifeClean International AB (publ), Annual General Meeting, Jun 30, 2025, at 13:00 W. Europe Standard Time. Location: at born advokaters premises, strandvagen 7a, 102 45 stockholm. Sweden New Risk • May 26
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 452% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr37m free cash flow). Share price has been highly volatile over the past 3 months (48% average weekly change). Negative equity (-kr12m). Earnings have declined by 34% per year over the past 5 years. Shareholders have been substantially diluted in the past year (452% increase in shares outstanding). Market cap is less than US$10m (kr50.2m market cap, or US$5.27m). Reported Earnings • May 21
First quarter 2025 earnings released First quarter 2025 results: Revenue: kr15.1m (down 4.8% from 1Q 2024). Net loss: kr9.17m (loss narrowed 39% from 1Q 2024). New Risk • Apr 23
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr43m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr43m free cash flow). Share price has been highly volatile over the past 3 months (49% average weekly change). Negative equity (-kr3.6m). Earnings have declined by 37% per year over the past 5 years. Market cap is less than US$10m (kr13.5m market cap, or US$1.41m). Reported Earnings • Feb 20
Full year 2024 earnings released: kr0.97 loss per share (vs kr0.94 loss in FY 2023) Full year 2024 results: kr0.97 loss per share (further deteriorated from kr0.94 loss in FY 2023). Revenue: kr62.0m (up 18% from FY 2023). Net loss: kr53.7m (loss widened 21% from FY 2023). Revenue is forecast to grow 36% p.a. on average during the next 2 years, compared to a 6.0% growth forecast for the Chemicals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 49% per year, which means it is performing significantly worse than earnings. Aankondiging • Feb 20
LifeClean International AB (publ), Annual General Meeting, Mar 21, 2025 LifeClean International AB (publ), Annual General Meeting, Mar 21, 2025, at 08:00 W. Europe Standard Time. Location: at born advokater`s premises, strandvagen 7a, 102 45, stockholm. Sweden New Risk • Dec 05
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: kr108.5m (US$9.97m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 39% per year over the past 5 years. Market cap is less than US$10m (kr108.5m market cap, or US$9.97m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-kr43m). Shareholders have been diluted in the past year (18% increase in shares outstanding). Price Target Changed • Nov 16
Price target increased by 437% to kr36.00 Up from kr6.70, the current price target is provided by 1 analyst. New target price is 1,381% above last closing price of kr2.43. Stock is down 63% over the past year. The company posted a net loss per share of kr0.94 last year. New Risk • Oct 27
New major risk - Revenue and earnings growth Earnings have declined by 39% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 39% per year over the past 5 years. Minor Risks Less than 1 year of cash runway based on current free cash flow (-kr43m). Shareholders have been diluted in the past year (18% increase in shares outstanding). Market cap is less than US$100m (kr207.5m market cap, or US$19.5m). Reported Earnings • Oct 25
Third quarter 2024 earnings: Revenues miss analyst expectations Third quarter 2024 results: Revenue: kr14.1m (up 39% from 3Q 2023). Net loss: kr13.3m (loss widened 11% from 3Q 2023). Revenue missed analyst estimates by 36%. Revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Chemicals industry in Sweden. New Risk • Sep 18
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Negative equity (-kr8.1m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-kr40m). Currently unprofitable and not forecast to become profitable over next 2 years (kr10m net loss in 2 years). Share price has been volatile over the past 3 months (8.3% average weekly change). Shareholders have been diluted in the past year (18% increase in shares outstanding). Market cap is less than US$100m (kr283.7m market cap, or US$27.8m). Major Estimate Revision • Sep 06
Consensus revenue estimates increase by 13% The consensus outlook for revenues in fiscal year 2024 has improved. 2024 revenue forecast increased from kr72.0m to kr81.4m. Forecast losses expected to reduce from -kr1.00 to -kr0.90 per share. Chemicals industry in Sweden expected to see average net income growth of 36% next year. Consensus price target up from kr6.70 to kr8.00. Share price rose 13% to kr5.94 over the past week. Breakeven Date Change • Sep 03
No longer forecast to breakeven The analyst covering LifeClean International no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of kr3.00m in 2026. New forecast suggests the company will make a loss of kr4.00m in 2026. Price Target Changed • Sep 02
Price target increased by 14% to kr8.00 Up from kr7.00, the current price target is provided by 1 analyst. New target price is 45% above last closing price of kr5.50. Stock is up 0.7% over the past year. The company is forecast to post a net loss per share of kr0.90 next year compared to a net loss per share of kr0.94 last year. Reported Earnings • Sep 01
Second quarter 2024 earnings released Second quarter 2024 results: Revenue: kr21.0m (up 47% from 2Q 2023). Net loss: kr12.8m (loss widened 21% from 2Q 2023). Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Chemicals industry in Sweden. New Risk • Aug 06
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-kr44m). Currently unprofitable and not forecast to become profitable over next 2 years (kr3.8m net loss in 2 years). Share price has been volatile over the past 3 months (8.5% average weekly change). Shareholders have been diluted in the past year (5.0% increase in shares outstanding). Market cap is less than US$100m (kr221.9m market cap, or US$21.0m). New Risk • Apr 09
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 6.3% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr40m free cash flow). Earnings have declined by 42% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (6.3% increase in shares outstanding). Revenue is less than US$5m (kr53m revenue, or US$5.0m). Market cap is less than US$100m (kr430.9m market cap, or US$40.9m). Reported Earnings • Feb 21
Full year 2023 earnings released: kr0.94 loss per share (vs kr0.83 loss in FY 2022) Full year 2023 results: kr0.94 loss per share (further deteriorated from kr0.83 loss in FY 2022). Revenue: kr52.5m (up 11% from FY 2022). Net loss: kr44.2m (loss widened 23% from FY 2022). Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Chemicals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings. Board Change • Feb 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. Independent Board Member Petra Sas was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Price Target Changed • Nov 28
Price target decreased by 29% to kr6.70 Down from kr9.50, the current price target is provided by 1 analyst. New target price is 29% above last closing price of kr5.20. Stock is down 43% over the past year. The company posted a net loss per share of kr0.83 last year. Reported Earnings • Nov 27
Third quarter 2023 earnings released Third quarter 2023 results: Revenue: kr10.4m (up 17% from 3Q 2022). Net loss: kr11.9m (loss widened 44% from 3Q 2022). Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Chemicals industry in Sweden. New Risk • Aug 31
New minor risk - Financial position The company has less than a year of cash runway based on its current free cash flow. Free cash flow: -kr33m This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-kr33m). Currently unprofitable and not forecast to become profitable over next 2 years (kr3.0m net loss in 2 years). Share price has been volatile over the past 3 months (9.5% average weekly change). Shareholders have been diluted in the past year (9.1% increase in shares outstanding). Revenue is less than US$5m (kr47m revenue, or US$4.3m). Market cap is less than US$100m (kr282.6m market cap, or US$25.8m). New Risk • Jul 28
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 9.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr5.0m net loss in 2 years). Share price has been volatile over the past 3 months (9.5% average weekly change). Shareholders have been diluted in the past year (9.1% increase in shares outstanding). Revenue is less than US$5m (kr48m revenue, or US$4.5m). Market cap is less than US$100m (kr341.2m market cap, or US$32.4m). Reported Earnings • Feb 19
Full year 2022 earnings released: kr0.83 loss per share (vs kr0.83 loss in FY 2021) Full year 2022 results: kr0.83 loss per share (further deteriorated from kr0.83 loss in FY 2021). Revenue: kr48.3m (down 18% from FY 2021). Net loss: kr36.1m (loss widened 1.0% from FY 2021). Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in Sweden. Board Change • Nov 16
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Board Member Petra Sas was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 06
Third quarter 2022 earnings released Third quarter 2022 results: Revenue: kr9.10m (down 21% from 3Q 2021). Net loss: kr8.31m (loss narrowed 1.3% from 3Q 2021). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 8.6% growth forecast for the Chemicals industry in Sweden. Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. No independent directors (4 non-independent directors). Board member Jan Sjowall was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Reported Earnings • Feb 18
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Full year 2021 results: kr0.78 loss per share (down from kr0.14 loss in FY 2020). Revenue: kr55.3m (up 69% from FY 2020). Net loss: kr32.8m (loss widened kr29.6m from FY 2020). Revenue missed analyst estimates by 52%. Reported Earnings • Nov 10
Third quarter 2021 earnings released The company reported a decent third quarter result with improved revenues, although losses increased and control over costs was weaker. Third quarter 2021 results: Revenue: kr12.1m (up 261% from 3Q 2020). Net loss: kr8.42m (loss widened 271% from 3Q 2020). Reported Earnings • Aug 20
Second quarter 2021 earnings released: kr0.15 loss per share (vs kr0.76 profit in 2Q 2020) The company reported a poor second quarter result with weaker earnings, revenues and control over costs. Second quarter 2021 results: Revenue: kr18.9m (down 3.2% from 2Q 2020). Net loss: kr6.36m (down 215% from profit in 2Q 2020). Reported Earnings • May 07
First quarter 2021 earnings released The company reported a poor first quarter result with weaker earnings, revenues and control over costs. First quarter 2021 results: Revenue: kr12.0m (down 6.9% from 1Q 2020). Net loss: kr6.99m (down 338% from profit in 1Q 2020). Reported Earnings • Mar 29
Full year 2020 earnings released: kr0.14 loss per share The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: kr32.7m (up kr29.0m from FY 2019). Net loss: kr3.20m (loss narrowed 69% from FY 2019). Reported Earnings • Feb 21
Full year 2020 earnings released: kr0.14 loss per share The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: kr32.7m (up kr29.0m from FY 2019). Net loss: kr3.20m (loss narrowed 69% from FY 2019). Is New 90 Day High Low • Jan 27
New 90-day low: kr9.60 The company is down 6.0% from its price of kr10.25 on 28 October 2020. The Swedish market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 11% over the same period. Is New 90 Day High Low • Jan 04
New 90-day low: kr9.79 The company is down 23% from its price of kr12.70 on 06 October 2020. The Swedish market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 5.0% over the same period. 
